<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39398138</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2470-1343</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>40</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>ACS omega</Title><ISOAbbreviation>ACS Omega</ISOAbbreviation></Journal><ArticleTitle>Inhibition of the SARS-CoV-2 Non-structural Protein 5 (NSP5) Protease by Nitrosocarbonyl-Bases Small Molecules.</ArticleTitle><Pagination><StartPage>41599</StartPage><EndPage>41615</EndPage><MedlinePgn>41599-41615</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsomega.4c05480</ELocationID><Abstract><AbstractText>In the present work, we have designed and synthesized potential NSP5 protease allosteric inhibitors exploiting both docking and molecular dynamic data on SARS-CoV-2. The chemical protocols were developed on the basis of 1,3-dipolar cycloaddition reactions as well as the chemistry of nitrosocarbonyl intermediates. Computational studies were first conducted for determining the best candidate for SARS-CoV-2 NSP5 protease inhibition. Selected compounds were submitted to biological tests, showing low cytotoxicity and moderate activity.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leusciatti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, INSTM Research Unit of Pavia; University of Pavia, Viale Taramelli 10-12, Pavia 27100, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biocomputing Lab, SCITEC-Istituto di Scienze e Tecnologie Chimiche CNR, Via Mario Bianco 9, Milano 20131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macchi</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Chemical Science and Technology, University of Rome Tor Vergata, Via della ricerca scientifica 1, Roma 00133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino-Merlo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, Messina 98166, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefanizzi</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, Messina 98166, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastino</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, 31, Messina 98166, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute of Translational Pharmacology, CNR, Via Fosso del Cavaliere 100, Roma 00133, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morra</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9681-7845</Identifier><AffiliationInfo><Affiliation>Biocomputing Lab, SCITEC-Istituto di Scienze e Tecnologie Chimiche CNR, Via Mario Bianco 9, Milano 20131, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quadrelli</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5369-9140</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, INSTM Research Unit of Pavia; University of Pavia, Viale Taramelli 10-12, Pavia 27100, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Omega</MedlineTA><NlmUniqueID>101691658</NlmUniqueID><ISSNLinking>2470-1343</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398138</ArticleId><ArticleId IdType="pmc">PMC11465462</ArticleId><ArticleId IdType="doi">10.1021/acsomega.4c05480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kandwal S.; Fayne D. Genetic conservation across SARS-CoV-2 non-structural proteins – Insights into possible targets for treatment of future viral outbreaks. Virology 2023, 581, 97–115. 10.1016/j.virol.2023.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2023.02.011</ArticleId><ArticleId IdType="pmc">PMC9999249</ArticleId><ArticleId IdType="pubmed">36940641</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxmen A. More than 80 clinical trials launch to test coronavirus treatments. Nature 2020, 578, 347–348. 10.1038/d41586-020-00444-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-00444-3</ArticleId><ArticleId IdType="pubmed">32071447</ArticleId></ArticleIdList></Reference><Reference><Citation>Leusciatti M.; Macchi B.; Marino-Merlo F.; Mastino A.; Morra G.; Quadrelli P. Inhibition of the RNA-dependent RNA-polymerase from SARS-CoV-2 by 6-chloropurine isoxazoline-carbocyclic monophosphate nucleotides. ACS Omega 2023, 8, 36311–36320. 10.1021/acsomega.3c04918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.3c04918</ArticleId><ArticleId IdType="pmc">PMC10552509</ArticleId><ArticleId IdType="pubmed">37810686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.; Yan L.; Huang Y.; Liu F.; Zhao Y.; Cao L.; Wang T.; Sun Q.; Ming Z.; Zhang L.; Ge J.; Zheng L.; Zhang Y.; Wang H.; Zhu Y.; Zhu C.; Hu T.; Hua T.; Zhang B.; Yang X.; Li J.; Yang H.; Liu Z.; Xu W.; Guddat L. W.; Wang Q.; Lou Z.; Rao Z. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020, 368, 779–782. 10.1126/science.abb7498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7498</ArticleId><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodsell D. S.RCSB PDB-101. 2020, doi:10.2210/rcsb_pdb/mom_2020_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.2210/rcsb_pdb/mom_2020_9</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal B.; Goyal D. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy. ACS Comb. Sci. 2020, 22, 297–305. 10.1021/acscombsci.0c00058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscombsci.0c00058</ArticleId><ArticleId IdType="pubmed">32402186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q.; Xiong Y.; Zhu G. H.; Zhang Y. N.; Zhang Y. W.; Huang P.; Ge G. B. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. MedComm 2022, 3, e15110.1002/mco2.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.151</ArticleId><ArticleId IdType="pmc">PMC9283855</ArticleId><ArticleId IdType="pubmed">35845352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannalire R.; Cerchia C.; Beccari A. R.; Di Leva F. S.; Summa V. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. J. Med. Chem. 2022, 65, 2716–2746. 10.1021/acs.jmedchem.0c01140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01140</ArticleId><ArticleId IdType="pmc">PMC7688049</ArticleId><ArticleId IdType="pubmed">33186044</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther S.; et al. (92 authors) X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 2021, 372, 642–646. 10.1126/science.abf7945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7945</ArticleId><ArticleId IdType="pmc">PMC8224385</ArticleId><ArticleId IdType="pubmed">33811162</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzyoud L.; Mahgoub R. E.; Mohamed F. E.; Ali B. R.; Ferreira J.; Rabeh W. M.; Atatreh N.; Ghattas M. A. The Discovery of Novel Small Oxindole-Based Inhibitors Targeting the SARS-CoV-2 Main Protease (Mpro). Chem. Biodiversity 2023, 20, e20230117610.1002/cbdv.202301176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.202301176</ArticleId><ArticleId IdType="pubmed">37861105</ArticleId></ArticleIdList></Reference><Reference><Citation>Arutyunova E.; Khan M. B.; Fischer C.; Lu J.; Lamer T.; Vuong W.; van Belkum M. J.; McKay R. T.; Tyrrell D. L.; Vederas J. C.; Young H. S.; Lemieux M. J. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 Mpro Dimer. J. Mol. Biol. 2021, 433, 16700310.1016/j.jmb.2021.167003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167003</ArticleId><ArticleId IdType="pmc">PMC8061786</ArticleId><ArticleId IdType="pubmed">33895266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb Y. N. Nirmatrelvir Plus Ritonavir: First Approval. Drugs 2022, 82, 585–591. 10.1007/s40265-022-01692-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01692-5</ArticleId><ArticleId IdType="pmc">PMC8933659</ArticleId><ArticleId IdType="pubmed">35305258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L.; Lin D.; Sun X.; Curth U.; Drosten C.; Sauerhering L.; Becker S.; Rox K.; Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020, 368, 409–412. 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzyoud L.; Ghattas M. A.; Atatreh N. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus. Agents. Drug Des. Devel. Ther. 2022, 16, 2463–2478. 10.2147/DDDT.S370574.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S370574</ArticleId><ArticleId IdType="pmc">PMC9356625</ArticleId><ArticleId IdType="pubmed">35941927</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrelli P. Eds. “Modern Applications of Cycloaddition Chemistry”, Elsevier: Amsterdam, 2019; pp 1–152.</Citation></Reference><Reference><Citation>Memeo M. G.; Quadrelli P. Generation and trapping of nitrosocarbonyl intermediates. Chem. Rev. 2017, 117, 2108–2200. 10.1021/acs.chemrev.6b00684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.6b00684</ArticleId><ArticleId IdType="pubmed">28105813</ArticleId></ArticleIdList></Reference><Reference><Citation>Moggio Y.; Legnani L.; Bovio B.; Memeo M. G.; Quadrelli P. Synthesis of novel anthracene derivatives of isoxazolino-carbocyclic nucleoside analogues. Tetrahedron 2012, 68, 1384–1392. 10.1016/j.tet.2011.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tet.2011.12.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrelli P.; Scrocchi R.; Caramella P.; Rescifina A.; Piperno A. From cyclopentadiene to isoxazoline–carbocyclic nucleosides: a rapid access to biological molecules through nitrosocarbonyl chemistry. Tetrahedron 2004, 60, 3643–3651. 10.1016/j.tet.2004.02.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tet.2004.02.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrelli P.; Mella M.; Carosso S.; Bovio B. N,O-Nucleosides from Ene Reactions of Nitrosocarbonyl Intermediates with the 3-Methyl-2-buten-1-ol. J. Org. Chem. 2013, 78, 516–526. 10.1021/jo302346a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jo302346a</ArticleId><ArticleId IdType="pubmed">23245669</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljaf K. K.; Amin A. A.; Hussain F. H. S.; Quadrelli P. DEAE-cellulose-catalyzed synthesis of 5-hydroxy-isoxazolidines and their synthetic uses towards nucleoside analogues. Arkivoc 2020, 2020, 73–83. 10.24820/ark.5550190.p011.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.24820/ark.5550190.p011.159</ArticleId></ArticleIdList></Reference><Reference><Citation>Morra G.; Neves M. A. C.; Plescia C. J.; Tsustsumi S.; Neckers L.; Verkhivker G.; Altieri D. C.; Colombo G. Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. J. Chem. Theory Comput. 2010, 6, 2978–2989. 10.1021/ct100334n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct100334n</ArticleId><ArticleId IdType="pmc">PMC7575213</ArticleId><ArticleId IdType="pubmed">26616092</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrens-Fontanals M.; Peralta-García A.; Talarico C.; Guixà-González R.; Giorgino T.; Selent J. SCoV2-MD: a database for the dynamics of the SARS-CoV-2 proteome and variant impact predictions. Nucleic Acids Res. 2022, 50, D858–D866. 10.1093/nar/gkab977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab977</ArticleId><ArticleId IdType="pmc">PMC8689960</ArticleId><ArticleId IdType="pubmed">34761257</ArticleId></ArticleIdList></Reference><Reference><Citation>del Sol A.; Tsai C.-J.; Ma B.; Nussinov R. The Origin of Allosteric Functional Modulation: Multiple Pre-existing Pathway. Structure 2009, 17, 1042–1050. 10.1016/j.str.2009.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2009.06.008</ArticleId><ArticleId IdType="pmc">PMC2749652</ArticleId><ArticleId IdType="pubmed">19679084</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu T.; Zhang Y.; Li L.; Wang K.; Chen S.; Chen J.; Ding J.; Jiang H. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology 2009, 388, 324–334. 10.1016/j.virol.2009.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.03.034</ArticleId><ArticleId IdType="pmc">PMC7103376</ArticleId><ArticleId IdType="pubmed">19409595</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Baba T. J.; Lutomski C. A.; Kantsadi A. L.; Malla T. R.; John T.; Mikhailov V.; Bolla J. R.; Schofield C. J.; Zitzmann N.; Vakonakis I.; Robinson C. V. Allosteric Inhibition of the SARS-CoV-2 Main Protease: Insights from Mass Spectrometry Based Assays. Angew. Chem., Int. Ed. 2020, 59, 23544–23548. 10.1002/anie.202010316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202010316</ArticleId><ArticleId IdType="pmc">PMC7461284</ArticleId><ArticleId IdType="pubmed">32841477</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrelli P.; Scrocchi R.; Caramella P.; Rescifina A.; Piperno A. From cyclopentadiene to isoxazoline–carbocyclic nucleosides: a rapid access to biological molecules through nitrosocarbonyl chemistry. Tetrahedron 2004, 60, 3643–3651. 10.1016/j.tet.2004.02.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tet.2004.02.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrelli P.; Mella M.; Carosso S.; Bovio B. From the Ene Reaction of Nitrosocarbonyl Intermediates with the 3-Methyl-but-2-en-1-ol, a New Class of Purine N. O-Nucleoside Analogues. Synthesis 2013, 45, 1414–1420. 10.1055/s-0032-1316916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1316916</ArticleId><ArticleId IdType="pubmed">23245669</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadrelli P.; Mella M.; Legnani L.; Al-Saad D. From Cyclopentadiene to Isoxazoline-Carbociclic Nucleosides; Synthesis of Highly Active Inhibitors of Influenza A Virus H1N1. Eur. J. Org. Chem. 2013, 2013, 4655–4665. 10.1002/ejoc.201300119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejoc.201300119</ArticleId></ArticleIdList></Reference><Reference><Citation>Memeo M. G.; Mella M.; Montagna V.; Quaderelli P. Design, Synthesis, and Conformational Analysis of Proposed β-Turn Mimics from Isoxazoline-Cyclopentane Aminols. Chem.—Eur. J. 2015, 21, 16374–16378. 10.1002/chem.201503062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/chem.201503062</ArticleId><ArticleId IdType="pubmed">26418579</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljaf K. K.; Amin A. A.; Hussain F. H. S.; Quadrelli P. Diethylaminoethyl cellulose (DEAE-C): applications in chromatography and in organic synthesis. Arkivoc 2020, 2020, 153–179. 10.24820/ark.5550190.p011.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.24820/ark.5550190.p011.310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C.; Sacco M. D.; Townsend J. A.; Hu Y.; Szeto T.; Zhang X.; Tarbet B.; Marty M. T.; Chen Y.; Wang J. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020, 30, 678–692. 10.1038/s41422-020-0356-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Caramella P.; Grünanger P.. 1,3-Dipolar Cycloaddition Chemistry.; Padwa A., Eds.; John Wiley &amp; Sons Inc.: New York, 1984, Vol. 1, p 291–392.</Citation></Reference><Reference><Citation>Grünanger P.; Finzi P. V.. Isoxazoles; John Wiley &amp; Sons, Inc.: New York, 1999, Vol. 1 and 2.</Citation></Reference><Reference><Citation>Grundmann C.; Grünanger P.. The Nitrile Oxides; Springer-Verlag: Heidelberg, 1971.</Citation></Reference><Reference><Citation>Presenti P.; Moiola M.; Quadrelli P. 5-Hydroxy-isoxazolidine: A New Synthetic Approach to a Privileged Heterocycle for Organic Synthesis. Chemistry Select 2020, 5, 5367–5373. 10.1002/slct.202001337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/slct.202001337</ArticleId></ArticleIdList></Reference><Reference><Citation>Scagnelli L.; Memeo M. G.; Carosso S.; Bovio B.; Quadrelli P. Syntheses of New Carbanucleosides by Pericyclic Reactions. Eur. J. Org. Chem. 2013, 3835–3846. 10.1002/ejoc.201300202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejoc.201300202</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saad D.; Memeo M. G.; Quadrelli P. Pericyclic Reactions for Anti-HPV Antivirals: Unconventional Nucleoside Analogue Synthesis via Nitrosocarbonyl Chemistry. Chemistry Select 2017, 2, 10340–10346. 10.1002/slct.201702059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/slct.201702059</ArticleId></ArticleIdList></Reference><Reference><Citation>Carella S.; Memeo M. G.; Quadrelli P. Electrocyclic Ring-Opening of 1,2,4-Oxadiazole[4,5-a]pyridinium Chloride: a New Route to 1,2,4-Oxadiazole Dienamino Compounds. Chemistry Open 2019, 8, 1209–1221. 10.1002/open.201900230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/open.201900230</ArticleId><ArticleId IdType="pmc">PMC6739692</ArticleId><ArticleId IdType="pubmed">31523609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantione D.; Aizpuru O. O.; Memeo M. G.; Bovio B.; Quadrelli P. 4-Heterosubstituted Cyclopentenone Antiviral Compounds: Synthesis, Mechanism, and Antiviral Evaluation. Eur. J. Org. Chem. 2016, 983–911. 10.1002/ejoc.201501406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejoc.201501406</ArticleId></ArticleIdList></Reference><Reference><Citation>Moggio Y.; Legnani L.; Bovio B.; Memeo M. G.; Quadrelli P. Synthesis of novel anthracene derivatives pf isoxazolino-carbocyclic nucleoside analogues. Tetrahedron 2012, 68, 1384–1392. 10.1016/j.tet.2011.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tet.2011.12.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Savion M.; Memeo M. G.; Bovio B.; Grazioso G.; Legnani L.; Quadrelli P. Synthesis and molecular modeling of novel dihydroxycyclopentane-carbonitrile nor-nucleosides by bromonitrile oxide 1,3-dipolar cycloaddition. Tetrahedron 2012, 68, 1854–1852. 10.1016/j.tet.2011.12.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tet.2011.12.086</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saad D.; Memeo M. G.; Quadrelli P. Pericyclic Reactions for Antivirals: Synthesis of 4-Bromo-N-[(1R*,4S*)-4-hydroxy-2-cyclohexen-1-yl]-2-thiazolecarboxamide. Lett. Org. Chem. 2017, 13, 757–763. 10.2174/1570178614666161128150457.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570178614666161128150457</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti M.; Leusciatti M.; Moiola M.; Mella M.; Quadrelli P. Nitrosocarbonyl Carbohydrate Derivatives: Hetero Diels-Alder and Ene Reaction Products for Useful Organic Synthesis. Synthesis 2021, 53, 574–586. 10.1055/s-0040-1707276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1707276</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saad D.; Memeo M. G.; Quadrelli P. #Nitrosocarbonyls 1: Antiviral Activity of N-(4-Hydroxycyclohex-2-en-1-yl)quinoline-2-carboxamide against the Influenza A Virus H1N1. Sci. World J. 2014, 47237310.1155/2014/472373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/472373</ArticleId><ArticleId IdType="pmc">PMC4293787</ArticleId><ArticleId IdType="pubmed">25610906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>